Novartis wins EU approval for multiple myeloma drug Farydak

September 4, 2015 10:39 AM

31 0

ZURICH Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has progressed following standard therapy.

Novartis received similar approval for Farydak from the U.S. Food and Drug Administration in February for treating multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow.

Read more

To category page